Co-Authors
This is a "connection" page, showing publications co-authored by AMIR A JAZAERI and KATHLEEN M SCHMELER.
Connection Strength
0.961
-
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. 2024 Aug 10.
Score: 0.245
-
Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med. 2024 Apr 12; 5(4):311-320.e3.
Score: 0.238
-
Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report. Case Rep Oncol. 2023 Jan-Dec; 16(1):273-278.
Score: 0.224
-
A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery? Gynecol Oncol. 2024 Sep; 188:120-124.
Score: 0.061
-
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
Score: 0.051
-
A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One. 2021; 16(3):e0247905.
Score: 0.048
-
Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel). 2021 Feb 24; 13(5).
Score: 0.048
-
Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. 2019 11; 155(2):237-244.
Score: 0.044